We are live on ! Find out more
ASTX

ASTEX PHARMACEUTICALS, INC COM
ASTX

Delisted

ASTX was delisted on the 10th of October, 2013.

Back to rankings

0 hedge funds and large institutions have $0 invested in ASTEX PHARMACEUTICALS, INC COM in 2013 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 123 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 123 → 0 (-123)

100% less capital invested

Capital invested by funds: $487M → $0 (-$487M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 123

Holders
–
Holders Change
-123
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
123
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BFA
BlackRock Fund Advisors
California
-$35.4M
2
BIT
BlackRock Institutional Trust
California
-$31.5M
3
TAL
TIG Advisors LLC
New York
-$30.8M
4
State Street
State Street
Massachusetts
-$30.1M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$27.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BFA
1
BlackRock Fund Advisors
California
– -$35.4M -4,174,298 Closed
BIT
2
BlackRock Institutional Trust
California
– -$31.5M -3,708,636 Closed
TAL
3
TIG Advisors LLC
New York
– -$30.8M -3,633,592 Closed
State Street
4
State Street
Massachusetts
– -$30.1M -3,543,911 Closed
Dimensional Fund Advisors
5
Dimensional Fund Advisors
Texas
– -$27.7M -3,271,711 Closed
CM
6
Corvex Management
New York
– -$20.7M -2,443,004 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$20.4M -2,404,209 Closed
Millennium Management
8
Millennium Management
New York
– -$20M -2,355,404 Closed
WIC
9
Water Island Capital
New York
– -$19.4M -2,291,426 Closed
SAM
10
Sandell Asset Management
New York
– -$17.9M -2,107,445 Closed
Barclays
11
Barclays
United Kingdom
– -$14.2M -1,770,479 Closed
AAA
12
Alpine Associates Advisors
New Jersey
– -$14.6M -1,719,600 Closed
JP Morgan Chase
13
JP Morgan Chase
New York
– -$11.7M -1,378,833 Closed
COPPSERS
14
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$11.4M -1,337,612 Closed
Franklin Resources
15
Franklin Resources
California
– -$9.85M -1,161,600 Closed
AQR Capital Management
16
AQR Capital Management
Connecticut
– -$9.68M -1,141,050 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$8.69M -1,023,273 Closed
Northern Trust
18
Northern Trust
Illinois
– -$8.66M -1,019,905 Closed
LIM
19
Longfellow Investment Management
Massachusetts
– -$8.41M -990,093 Closed
Invesco
20
Invesco
Georgia
– -$7.91M -931,641 Closed
SBH
21
Segall Bryant & Hamill
Illinois
– -$6.8M -800,962 Closed
CS
22
Credit Suisse
Switzerland
– -$5.94M -699,208 Closed
SIS
23
Sandell Investment Services
New York
– -$5.49M -646,089 Closed
CI
24
Cowen Inc
New York
– -$5.34M -628,972 Closed
Goldman Sachs
25
Goldman Sachs
New York
– -$4.96M -584,741 Closed
1
2 3 4 5

ASTX Hedge Fund Activity: Q4 2013 in Review

0 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in ASTEX PHARMACEUTICALS, INC COM (ASTX) for Q4 2013, worth a combined $0 — down 100% from $487M a quarter earlier.

Sellers outnumbered buyers: 123 funds closed out of ASTX and 0 opened new positions — a net loss of 123 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock Fund Advisors, exiting entirely with an estimated $35.4M sold.

  • 0 institutional investors held ASTEX PHARMACEUTICALS, INC COM (ASTX) as of Q4 2013, down from 123 in Q3 2013.
  • Funds reported $0 of ASTEX PHARMACEUTICALS, INC COM stock for Q4 2013, down 100% quarter-over-quarter.
  • 0 funds opened new ASTEX PHARMACEUTICALS, INC COM positions in Q4 2013 and 123 closed out, a net change of -123 holders.
  • The largest ASTEX PHARMACEUTICALS, INC COM seller in Q4 2013 was BlackRock Fund Advisors, an estimated $35.4M sold.

Based on aggregated 13F filings for Q4 2013.